1. Home
  2. VRAX vs BGLC Comparison

VRAX vs BGLC Comparison

Compare VRAX & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRAX
  • BGLC
  • Stock Information
  • Founded
  • VRAX 2013
  • BGLC 2017
  • Country
  • VRAX United Kingdom
  • BGLC Malaysia
  • Employees
  • VRAX N/A
  • BGLC N/A
  • Industry
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • BGLC Medical Specialities
  • Sector
  • VRAX Health Care
  • BGLC Health Care
  • Exchange
  • VRAX Nasdaq
  • BGLC Nasdaq
  • Market Cap
  • VRAX 7.8M
  • BGLC 7.6M
  • IPO Year
  • VRAX 2022
  • BGLC N/A
  • Fundamental
  • Price
  • VRAX $2.37
  • BGLC $0.26
  • Analyst Decision
  • VRAX
  • BGLC
  • Analyst Count
  • VRAX 0
  • BGLC 0
  • Target Price
  • VRAX N/A
  • BGLC N/A
  • AVG Volume (30 Days)
  • VRAX 198.4K
  • BGLC 1.5M
  • Earning Date
  • VRAX 02-05-2025
  • BGLC 11-15-2024
  • Dividend Yield
  • VRAX N/A
  • BGLC N/A
  • EPS Growth
  • VRAX N/A
  • BGLC N/A
  • EPS
  • VRAX N/A
  • BGLC N/A
  • Revenue
  • VRAX $84,872.00
  • BGLC $9,259,858.00
  • Revenue This Year
  • VRAX $5,169.18
  • BGLC N/A
  • Revenue Next Year
  • VRAX $66.97
  • BGLC N/A
  • P/E Ratio
  • VRAX N/A
  • BGLC N/A
  • Revenue Growth
  • VRAX 7.03
  • BGLC N/A
  • 52 Week Low
  • VRAX $0.60
  • BGLC $0.23
  • 52 Week High
  • VRAX $9.00
  • BGLC $3.39
  • Technical
  • Relative Strength Index (RSI)
  • VRAX 64.60
  • BGLC 40.08
  • Support Level
  • VRAX $1.51
  • BGLC $0.25
  • Resistance Level
  • VRAX $1.98
  • BGLC $0.28
  • Average True Range (ATR)
  • VRAX 0.18
  • BGLC 0.05
  • MACD
  • VRAX 0.03
  • BGLC 0.00
  • Stochastic Oscillator
  • VRAX 98.85
  • BGLC 10.75

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

About BGLC BioNexus Gene Lab Corp Common stock

BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.

Share on Social Networks: